Cansortium Inc
FLUENT Corp., through its subsidiaries, cultivates, manufactures processes, distributes, and sells medical cannabis products for medical and adult-use markets in Florida, New York, Pennsylvania, and Texas. The company's medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, edibles, and other accessories under the Flue… Read more
Cansortium Inc (CNTMF) - Net Assets
Latest net assets as of September 2025: $-40.56 Million USD
Based on the latest financial reports, Cansortium Inc (CNTMF) has net assets worth $-40.56 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($203.63 Million) and total liabilities ($244.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-40.56 Million |
| % of Total Assets | -19.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | -132.27% |
| 10-Year Change | N/A |
| Growth Volatility | 186.2 |
Cansortium Inc - Net Assets Trend (2016–2024)
This chart illustrates how Cansortium Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cansortium Inc (2016–2024)
The table below shows the annual net assets of Cansortium Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-8.98 Million | -204.62% |
| 2023-12-31 | $8.59 Million | -68.85% |
| 2022-12-31 | $27.56 Million | -55.95% |
| 2021-12-31 | $62.57 Million | +124.81% |
| 2020-12-31 | $27.83 Million | -41.01% |
| 2019-12-31 | $47.18 Million | -28.20% |
| 2018-12-31 | $65.71 Million | +457.49% |
| 2017-12-31 | $11.79 Million | +102.57% |
| 2016-12-31 | $5.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cansortium Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25631923700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $249.23 Million | % |
| Total Equity | $-8.98 Million | 100.00% |
Cansortium Inc Competitors by Market Cap
The table below lists competitors of Cansortium Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MOBILE FACTORY INC
F:2MF
|
$22.27 Million |
|
BE Group AB
ST:BEGR
|
$22.27 Million |
|
PARKMEAD GROUP LS-015
F:LYK1
|
$22.27 Million |
|
Satori Resources Inc
OTCQB:STRRF
|
$22.28 Million |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
$22.25 Million |
|
King River Resources Ltd
AU:KRR
|
$22.25 Million |
|
XTPL SA
WAR:XTP
|
$22.25 Million |
|
Yeou Yih Steel Co Ltd
TWO:9962
|
$22.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cansortium Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,585,000 to -8,982,000, a change of -17,567,000 (-204.6%).
- Net loss of 40,390,000 reduced equity.
- Other factors increased equity by 22,823,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.39 Million | -449.68% |
| Other Changes | $22.82 Million | +254.1% |
| Total Change | $- | -204.62% |
Book Value vs Market Value Analysis
This analysis compares Cansortium Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.88 | $0.06 | x |
| 2019-12-31 | $0.47 | $0.06 | x |
| 2020-12-31 | $0.23 | $0.06 | x |
| 2021-12-31 | $0.25 | $0.06 | x |
| 2022-12-31 | $0.10 | $0.06 | x |
| 2023-12-31 | $0.03 | $0.06 | x |
| 2024-12-31 | $-0.01 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cansortium Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.00%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-91.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -35.28% | 0.00% | 0.00x | 1.04x | $-2.65 Million |
| 2017 | -84.48% | 0.00% | 0.00x | 1.51x | $-11.33 Million |
| 2018 | -0.49% | -4.06% | 0.06x | 2.12x | $-6.95 Million |
| 2019 | -138.01% | -229.15% | 0.17x | 3.53x | $-70.07 Million |
| 2020 | -131.58% | -69.90% | 0.34x | 5.55x | $-39.40 Million |
| 2021 | -30.43% | -29.10% | 0.36x | 2.92x | $-25.30 Million |
| 2022 | -135.79% | -42.68% | 0.49x | 6.46x | $-40.18 Million |
| 2023 | -265.00% | -23.38% | 0.55x | 20.71x | $-23.61 Million |
| 2024 | 0.00% | -39.00% | 0.50x | 0.00x | $-39.49 Million |
Industry Comparison
This section compares Cansortium Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cansortium Inc (CNTMF) | $-40.56 Million | -35.28% | N/A | $22.25 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |